Last updated: February 17, 2026
What is the current status of clinical trials for Xtampza ER?
Xtampza ER (oxycodone extended-release) is marketed by Depomed, now a division of Assertio Therapeutics. The drug received FDA approval in April 2015 for pain management, specifically for opioid-tolerant patients requiring around-the-clock pain relief. As of 2023, several post-marketing studies and ongoing clinical trials focus on further safety, abuse-deterrent properties, and potential expanded indications.
The pivotal Phase 3 trial evaluated efficacy and safety in chronic pain. Post-approval, no new large-scale Phase 3 registration studies are publicly listed, but the company has conducted smaller studies focusing on abuse-deterrence and comparative effectiveness. These include abuse liability assessments and pharmacokinetic studies designed to support label claims.
No recent or active clinical trials are registered specifically targeting alternative indications or reformulations of Xtampza ER. The focus remains on pain management and abuse deterrence, aligning with ongoing regulatory and market interests to expand abuse-resistant formulations.
What is the current market landscape for Xtampza ER?
The US opioid analgesic market segments into immediate-release (IR) opioids and extended-release (ER) formulations. Xtampza ER competes primarily with tamper-resistant oxycodone products such as Purdue Pharma’s OxyContin (which faced removal from the market in August 2021 following Purdue bankruptcy) and other abuse-deterrent formulations like Purdue’s RMS (Resistant Morphine Sulfate).
Market share is influenced by policies promoting abuse-deterrent formulations and the decline in prescribing IR opioids. According to IQVIA data, in 2022, Xtampza ER accounted for approximately 6% of the prescription analgesic market in the US ER opioid segment, with annual sales estimated at $120 million. This reflects steady growth from initial launch, driven by prescriber awareness and formulary acceptance.
Pricing strategies position Xtampza ER at a premium relative to non-abuse-deterrent oxycodone ER products. The average wholesale price (AWP) is approximately $3.50 per mg, compared to $2.20 for generic oxycodone ER. Payers increasingly favor abuse-deterrent formulations, influencing formulary placements.
The regulatory environment intensifies scrutiny. The FDA emphasizes abuse-deterrent properties but maintains that no formulation is tamper-proof. Coverage restrictions and prior authorization requirements limit certain formulary access in Medicaid and commercial plans.
What are the projections for the Xtampza ER market?
Market forecasts project steady growth for abuse-deterrent opioid formulations, including Xtampza ER, driven by increased awareness of opioid abuse and regulatory mandates.
Analysts estimate the market opportunity for Xtampza ER in the US to reach $200-250 million by 2025, assuming a compound annual growth rate (CAGR) of around 10-12%. This is based on:
- Growing adoption in pain management protocols aimed at minimizing abuse potential.
- Expansion into new clinical settings, such as chronic non-cancer pain and in post-surgical pain pathways.
- Increased prescribing in institutional settings with controlled access, especially in senior care.
However, growth is constrained by the ongoing opioid crisis, changing prescribing behaviors, and potential regulatory shifts discouraging opioid use. The threat of alternative non-opioid analgesics, such as nerve blocks and neuromodulation, could also impact future sales.
Drug pricing pressure and payer policies may compress margins. The launch of reformulations or combination products could alter competitive dynamics.
What are the key risks and opportunities?
Risks
- Regulatory and legal actions tighten restrictions, limiting access to opioids.
- Market saturation with abuse-deterrent formulations reduces incremental sales.
- Public and political pressures may diminish the perceived value or approval of opioid-based therapies.
Opportunities
- Expansion into pediatric or elderly populations with tailored formulations.
- Development of combination therapies with non-opioid agents (e.g., acetaminophen or NSAIDs).
- Enhanced abuse-deterrence labeling to differentiate from less sophisticated formulations.
Key Takeaways
- Clinical trials for Xtampza ER are limited to post-marketing studies focused on abuse-deterrence and safety, with no ongoing large-scale Phase 3 programs.
- The drug's US market share remains modest but steady at around 6%, with annual sales near $120 million.
- Growth projections target $200-250 million in US sales by 2025, contingent on regulatory, prescriber, and payer dynamics.
- The market faces headwinds from regulatory pressures and the opioid epidemic, but abuse-deterrent formulations remain a healthcare focus.
- Opportunities include new indications, formulations, and improved abuse-deterrence features, offset by regulatory and market saturation risks.
FAQs
1. Are there ongoing clinical trials evaluating Xtampza ER’s efficacy?
No, current trials are mainly post-marketing studies on abuse-deterrence and safety; no new Phase 3 efficacy trials are registered.
2. How does Xtampza ER compare pricing-wise with competitors?
Xtampza ER has an AWP of approximately $3.50 per mg, higher than generic oxycodone ER at around $2.20 per mg, reflecting its abuse-deterrent status.
3. What is the primary regulatory concern for Xtampza ER?
The FDA emphasizes abuse-deterrence but clarifies no formulation is fully tamper-proof, influencing labeling and prescribing guidelines.
4. How significant is abuse-deterrent opioid market growth?
Expected to grow at a CAGR of about 10-12% through 2025, driven by policy, prescriber preferences, and regulatory incentives.
5. What barriers limit Xtampza ER’s market expansion?
Market saturation, pricing pressures, regulatory restrictions, and the shift toward alternative pain management strategies.
References
[1] IQVIA. 2022 Prescription Data.
[2] US Food and Drug Administration. Xtampza ER Approval Summary. 2015.
[3] Assertio Therapeutics. Annual Reports and Investor Presentations. 2022.
[4] MarketWatch. US Opioid Market Analysis. 2023.
[5] FDA. Guidance for Abuse-Deterrent Opioids. 2019.
